

### Summary of Safety & Effectiveness SYNCHRON® Systems DAT Low and High Urine Calibrators II

### 1.0 Submitted By:

Lucinda Stockert
Staff Regulatory Specialist, Product Submissions
Beckman Coulter, Inc.
200 S. Kraemer Blvd., W-104
Brea, California 92822-8000
Telephone: (714) 961-3777
FAX: (714) 961-4123

#### 2.0 <u>Date Submitted</u>:

October 21, 1998

## 3.0 <u>Device Name(s)</u>:

### 3.1 Proprietary Names

SYNCHRON® Systems DAT Low and High Urine Calibrators II

### 3.2 Classification Name

Clinical Toxicology Calibrator (21 CFR §862.3200)

### 4.0 **Predicate Device(s)**:

SYNCHRON Systems Reagent	Predicate	Manufacturer	Docket Number
SYNCHRON® Systems DAT Low and High Urine Calibrators II	Drugs of Abuse Urine Calibrators A	Diagnostic Reagents, Inc.*	K935101

<sup>\*</sup>Diagnostic Reagents, Inc. Sunnyvale, CA

### 5.0 <u>Description</u>:

The SYNCHRON® Systems DAT Low and High Urine Calibrators II are used for calibration of Drugs of Abuse reagents in the clinical laboratory. This product contains a 5 mL bottle of the Low Urine Calibrator II and a 5 mL bottle of the High Urine Calibrator II. The storage temperature for the calibrators is +2°C to +8°C.

Beckman Coulter, Inc. 200 S. Kraemer Boulevard P.O. Box 8000 Brea, CA 92822-8000 Telephone: (714) 993-5321 Facsimile: (714) 961-4165

Internet: www.beckmancoulter.com

### 5.0 Intended Use:

The SYNCHRON® Systems DAT Low and High Urine Calibrators II, in conjunction with SYNCHRON Reagents, are intended for use on SYNCHRON Systems for the calibrations of Barbiturates, Benzodiazepine, Methadone, Opiate 300 ng, Methaqualone, and Propoxyphene enzyme immunoassays.

### 7.0 Comparison to Predicate(s):

Identical to predicate product (labeled for Beckman Coulter, Inc.) with the addition of the Opiate analyte.

# 8.0 **Summary of Performance Data:**

The data in the Premarket Notification on safety and effectiveness supports a finding of substantial equivalence to toxicology calibrators already in commercial distribution. Stress stability studies of the DAT Low and High Urine Calibrators II support the Beckman stability claim of 12 months.

This summary of safety and effectiveness is being submitted in accordance with the requirements of the Safe Medical Device Act of 1990 and the implementing regulation 21 CFR 807.92.

file: op\_call\_sse.doc





DEC 3 0 1998

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Lucinda Stockert Staff Regulatory Specialist Beckman Coulter, Inc. 200 S. Kraemer Boulevard, W-104 Brea, CA 92822

Re: K983747

Trade Name: SYNCHRON® Systems DAT Low and High Urine Calibrators II

Regulatory Class: II Product Code: DKB Dated: October 21, 1998 Received: October 23, 1998

### Dear Ms. Stockert:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for <u>in vitro</u> diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"

Sincerely yours,

Steven I. Gutman, M.D., M.B.A.

Director

Division of Clinical Laboratory Devices

Steven Butman

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

K983747

510(k) Number (if known): Not yet assigned.

Device Name: SYNCHRON® Systems DAT Low and High Urine Calibrators II

Indications for Use:

The SYNCHRON® Systems DAT Low and High Urine Calibrators II, in conjunction with SYNCHRON Reagents, are intended for use on SYNCHRON Systems for the calibrations of Barbiturates, Benzodiazepine, Methadone, Opiate 300 ng, Methagualone, and Propoxyphene enzyme immunoassays.

# 21 CFR 862.3200 Clinical Toxicology Calibrator

- (a) Identification. A clinical toxicology calibrator is a device intended for medical purposes for use in a test system to establish points of reference that are used in the determination of values in the measurement of substances in human specimens. A clinical toxicology calibrator can be a mixture of drugs or a specific material for a particular drug.
- (b) Classification. Class II.

EASE [	OO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDE
	Concurrence of CDRH, Office of Device Evaluation (ODE)
	Poticio Barlacot
	(Division Sign-Off)
	Division of Clinical Laboratory Devices
	510(k) Number 15 9 8 3747

Prescription Use \_\_\_\_\_ (per 21 CFR 801.109)

OR

Over-the-Counter Use \_\_\_\_\_ Optional Format 1-2-96